# Regulatory Post-Marketing Surveillance Study for TETRAXIM™

> **NCT01437423** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 600 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Poliomyelitis

## Interventions

- **BIOLOGICAL:** TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio

## Key facts

- **NCT ID:** NCT01437423
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2022-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01437423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01437423, "Regulatory Post-Marketing Surveillance Study for TETRAXIM™". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01437423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*